Ultra-high-field (7T) MRI can detect multiple sclerosis lesions better than MRI which can lead to possible earlier diagnosis and treatment, according to a new study by researchers from Ohio State University in Columbus, and Columbia University in New York.
For the study, the researchers analyzed post-mortem brain slices from a multiple sclerosis patient using both 3T and 7T MRI. 7T MRI made it possible to detect numerous multiple sclerosis lesions that were not detectable at 3T MRI, said Steffen Sammet, MD, PhD, lead author of the study.
"Multiple sclerosis is difficult to diagnose in its early stages," said Dr. Sammet. The greater sensitivity of 7T MRI for multiple sclerosis can delay disease conversion, and may lead to improved monitoring of neurological deficits in multiple sclerosis. MRI at 7T can give additional information about the lesion microstructure to help us better understand the disease," said Dr. Sammet.
"Ultra-high field strength has been an experimental methodology evolving over the last decade. In recent years, and especially as part of the OSU-based effort of the Wright Center of Innovation, we have been pushing, to evolve ultra-high field into a clinically capable imaging method. The significant advantage of higher field strength is the gain in signal that can be used in many different ways to increase sensitivity and increase the speed of acquisition or to increase resolution," said Dr. Sammet.
Source: American Roentgen Ray Society
Related stories:
Multiple Sclerosis: new MRI contrast medium enables early diagnosis in animal model
In an animal model of multiple sclerosis (MS), neuroradiologists and neurologists of the University hospitals of Heidelberg and Würzburg have been able to visualize inflammatory tissue damage, most of which had remained unrecognized up to now, with the aid of a new contrast medium, Gadofluorine M, in magnetic resonance imaging. The scientists have published their results in the online edition of the renowned medical journal
Brain.
Best treatment for MS may depend on disease subtype
Animal studies by University of Michigan scientists suggest that people who experience the same clinical signs of multiple sclerosis (MS) may have different forms of the disease that require different kinds of treatment.
Developing unique brain maps to assist surgery and research
Researchers from the Howard Florey Institute in Melbourne are developing new technology to create individualised brain maps that will revolutionise diagnosis of disease and enhance the accuracy of brain surgery.
'HiCy' drug regimen reverses ms symptoms in selected patients
A short-term, very-high dose regimen of the immune-suppressing drug cyclophosphamide seems to slow progression of multiple sclerosis (MS) in most of a small group of patients studied and may even restore neurological function lost to the disease, Johns Hopkins researchers report. The findings in nine people, most of whom had failed all other treatments, suggest new ways to treat a disease that tends to progress relentlessly.
High-dose immunosuppressant drug may reduce disability in MS patients
Treatment with high doses of the immunosuppressant drug cyclophosphamide appears to reduce disease activity and disability in individuals with aggressive multiple sclerosis, according to an article posted online today that will appear in the August 2008 print issue of
Archives of Neurology.
Prozac may help to curb disease activity in multiple sclerosis
The antidepressant Prozac may help to curb disease activity in the relapsing remitting form of multiple sclerosis (MS), reveals preliminary research published ahead of print in the
Journal of Neurology Neurosurgery and Psychiatry.
Researchers publish MRI images of genes in action in the living brain
Biologists have just confirmed what poets have known for centuries: eyes really are windows of the soul—or at least of the brain. In a new study published in the April 2008 print issue of
The FASEB Journal, Harvard researchers describe the development of gene probe eye drops that—for the first time—make it possible to monitor and detect tissue repair in the brain of living organisms using MRI. Current methods involve a risky, invasive, and relatively slow process of penetrating the skull to extract tissue samples and then examining those samples in a laboratory.
Increased level of magnetic iron oxides found in Alzheimer's disease
A team of scientists, led by Professor Jon Dobson, of Keele University in Staffordshire, UK, have found, for the first time, raised levels of magnetic iron oxides in the part of the brain affected by Alzheimer's Disease (AD).